No impact of passive smoke on the somatic profile of lung cancers in never-smokers

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1415-1425

  Couraud, Sébastien ^a   Debieuvre, Didier ^a   Moreau, Lionel ^a   Dumont, Patrick ^a   Margery, Jacques ^a   Quoix, Elisabeth ^a   Duvert, Bernard ^a   Cellerin, Laurent ^a   Baize, Nathalie ^a   Taviot, Bruno ^a   Coudurier, Marie ^a   Cadranel, Jacques ^a   Missy, Pascale ^a   Morin, Franck ^a   Mornex, Jean François ^a   Zalcman, Gérard ^a   Souquet, Pierre Jean ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; BIOLOGICAL MARKER; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PASSIVE SMOKING; PIK3CA PROTEIN, HUMAN; PROTEIN P21; PROTEIN TYROSINE KINASE;

AGED; ALK GENE; ARTICLE; BRAF GENE; CONTROLLED STUDY; EGFR GENE; FEMALE; HER2 GENE; HUMAN; KRAS GENE; LUNG CANCER; LUNG CANCER IN NEVER SMOKER; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; OBSERVATIONAL STUDY; PASSIVE SMOKING; PIK3CA GENE; PRIORITY JOURNAL; SOMATIC MUTATION; ADENOCARCINOMA; CLINICAL TRIAL; FRANCE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUTATION; PROSPECTIVE STUDY; QUESTIONNAIRE; SMOKING;

ADENOCARCINOMA; AGED; BIOMARKERS; FEMALE; FRANCE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SMOKING; SURVEYS AND QUESTIONNAIRES; TOBACCO SMOKE POLLUTION;

EID: 84929008929     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00097314     Document Type: Article

References (27)

1. Oberg M, Jaakkola MS, Woodward A, et al. Worldwide burden of disease from exposure to second-hand smoke: A retrospective analysis of data from 192 countries. Lancet 2011; 377: 139-146.
2. Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never smokers - A review. Eur J Cancer 2012; 48: 1299-1311.
3. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997; 315: 980-988.
4. Vineis P, Airoldi L, Veglia F, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 2005; 330: 277.
5. Brennan P, Buffler PA, Reynolds P, et al. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: A pooled analysis of two large studies. Int J Cancer 2004; 109: 125-131.
6. Clément-Duchêne C, Vignaud J-M, Stoufflet A, et al. Characteristics of never smoker lung cancer including environmental and occupational risk factors. Lung Cancer 2010; 67: 144-150.
7. Couraud S, Souquet P-J, Paris C, et al. BioCAST/IFCT-1002: Epidemiological and molecular features of lung cancer in never-smokers. Eur Respir J 2015; 45: 1403-1414.
8. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180.
9. Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors a HER2 Mutation: Epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31: 1997-2003.
10. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
11. Mounawar M, Mukeria A, Le Calvez F, et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007; 67: 5667-5672.
12. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29: 2046-2051.
13. Lee YJ, Cho BC, Jee SH, et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 2010; 28: 487-492.
14. Kawaguchi T, Ando M, Kubo A, et al. Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. Clin Cancer Res 2011; 17: 39-45.
15. Taga M, Mechanic LE, Hagiwara N, et al. EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- And never-smoking U.S. women. Cancer Epidemiol Biomarkers Prev 2012; 21: 988-992.
16. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006; 12: 1647-1653.
17. Couraud S, Souquet P-J, Paris C, et al. The BioCAST/IFCT-1002 study: A comprehensive overview of demographic, risk exposure and somatic mutations of non-small cell lung cancer occurring among French never smokers. J Thorac Oncol 2013; 8: Suppl. 2, S207-S208.
18. Couraud S, Labonne S, Missy P, et al. BioCAST: le Bio-observatoire national du cancer bronchiques chez les patients non fumeurs (IFCT1002) [Lung cancer in never smokers: A French national cohort (BioCAST/IFCT-1002)]. Rev Mal Respir 2013; 30: 576-583.
19. Bourgkard E, Wild P, Gonzalez M, et al. Comparison of exposure assessment methods in a lung cancer case-control study: performance of a lifelong task-based questionnaire for asbestos and PAHs. Occup Environ Med 2013; 70: 884-891.
20. Nowak F, Soria J-C, Calvo F. Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 2012; 9: 479-486.
21. Beau-Faller M, Blons H, Domerg C, et al. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting - IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms. J Mol Diagn 2014; 16: 45-55.
22. Kubo A, Masahiko A, Ross S, et al. Impacts of environmental tobacco smoke on EGFR mutations and ALK rearrangements in never smokers with non-small cell lung cancer: Analyses on a prospective multinational ETS registry. J Thorac Oncol 2013; 8: Suppl. 2, S1-S1410.
23. Besaratinia A, Pfeifer GP. Second-hand smoke and human lung cancer. Lancet Oncol 2008; 9: 657-666.
24. Thomas JL, Guo H, Carmella SG, et al. Metabolites of a tobacco-specific lung carcinogen in children exposed to secondhand or thirdhand tobacco smoke in their homes. Cancer Epidemiol Biomarkers Prev 2011; 20: 1213-1221.
25. Bennett WP, Alavanja MC, Blomeke B, et al. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst 1999; 91: 2009-2014.
26. Ryan BM, Wang Y, Jen J, et al. Evidence that the lung Adenocarcinoma EML4-ALK fusion gene is not caused by exposure to secondhand tobacco smoke during childhood. Cancer Epidemiol Biomarkers Prev 2014; 23: 1432-1434.
27. Krishnan VG, Ebert PJ, Ting JC, et al. Whole-genome sequencing of Asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers. Cancer Res 2014; 74: 6071-6081.